On November 7, 2022 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, reported that the company will host a key opinion leader (KOL) webinar, "Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint," on Monday, November 21, 2022 at 2:15 p.m. ET (Press release, Sensei Biotherapeutics, NOV 7, 2022, View Source [SID1234623277]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webinar will feature Robert Schreiber, Ph.D., Andrew M. and Jane M. Distinguished Professor of Pathology and Immunology at the Washington University School of Medicine, and member, Sensei Bio Immuno-oncology Advisory Board, who will provide background on VISTA (V-domain Immunoglobulin Suppressor of T cell Activation), discuss the unmet medical needs present in the current immuno-oncology treatment landscape and present on the importance of VISTA in developing highly selective therapeutics.
Sensei management will also provide an overview of its lead program SNS-101, a conditionally active, pH-sensitive VISTA-blocking antibody, including a review of preclinical data. SNS-101 is being developed to selectively block the VISTA checkpoint within a low-pH tumor microenvironment.
Participants may register in advance for the event online. A recording of the presentation will be made available on the Sensei website following the event.
The event will conclude with a Fireside Chat with Dr. Schreiber, moderated by Neil Canavan (Managing Director, LifeSci Advisors), followed by a live Q&A session. If you would like to ask a question during the live Q&A, please submit your request to [email protected].
Robert Schreiber, Ph.D., is the Andrew M. and Jane M. Distinguished Professor of Pathology and Immunology; Professor, Molecular Microbiology; and Director of the Bursky Center for Human Immunology and Immunotherapy Programs at the Washington University School of Medicine. He is also co-leader of the Tumor Immunology Program of Washington University’s Siteman Comprehensive Cancer Center, an Associate Director of the Scientific Advisory Board to the Cancer Research Institute and Co-editor-in-Chief of the Journal of Cancer Immunology Research. Dr. Schreiber’s group defined the concept of cancer immunoediting and is currently focused on elucidating the biochemistry and molecular cell biology of naturally occurring and therapeutically induced immune responses to developing and established tumors. Dr. Schreiber obtained his Ph.D. in Immunology/Biochemistry at the State University of New York in Buffalo, New York and received his postdoctoral training at The Scripps Research Institute in La Jolla, California.